SNGX - ソリジェニックス (Soligenix Inc.)

SNGXのニュース

   Soligenix Gets FDA Nod For Mid-Stage Psoriasis Study  2022/06/28 14:07:34 Benzinga
The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ: SNGX ) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients with Mild-to-Moderate Psoriasis. This study is designed to evaluate the safety and efficacy of topically-applied SGX302 (synthetic hypericin), will enrol up to 32 patients age 18 years … Full story available on Benzinga.com
   Soligenix adds 11% FDA nod to start mid-stage trial for psoriasis candidate  2022/06/28 11:57:18 Seeking Alpha
Clinical-stage biotech Soligenix (SNGX) added ~11% in the pre-market Tuesday after the company announced that the FDA cleared its investigational new drug ((IND)) application to start…
   Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis  2022/06/07 13:04:36 The Fintech Buzz
Strategy supports global need and has potential use in growing home healthcare market New York, New York–(Newsfile Corp. – June 7, 2022) – PCG Digital — Rising to the challenge in 2022, late-stage biopharma company Soligenix (NASDAQ: SNGX) continues to move forward with developing and commercializing products to treat rare diseases where there is an […]
   Soligenix to Present at the H.C. Wainwright Global Investment Conference  2022/05/18 11:30:00 PR Newswire
PRINCETON, N.J., May 18, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company…
   Soligenix GAAP EPS of -$0.10 misses by $0.03, revenue of $0.2M beats by $0.1M  2022/05/13 11:46:19 Seeking Alpha
Soligenix press release (SNGX): Q1 GAAP EPS of -$0.10 misses by $0.03.Revenue of $0.2M (+100.0% Y/Y) beats by $0.1M.
   Soligenix to Present at the H.C. Wainwright Global Investment Conference  2022/05/18 11:30:00 PR Newswire
PRINCETON, N.J., May 18, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company…
   Soligenix GAAP EPS of -$0.10 misses by $0.03, revenue of $0.2M beats by $0.1M  2022/05/13 11:46:19 Seeking Alpha
Soligenix press release (SNGX): Q1 GAAP EPS of -$0.10 misses by $0.03.Revenue of $0.2M (+100.0% Y/Y) beats by $0.1M.
   Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results  2022/05/13 11:30:00 PR Newswire
PRINCETON, N.J., May 13, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent…
   Soligenix GAAP EPS of -$0.31 misses by $0.01, revenue of $0.8M beats by $0.08M  2022/03/29 11:57:59 Seeking Alpha
Soligenix press release (SNGX): FY GAAP EPS of -$0.31 misses by $0.01.Revenue of $0.8M (-66.7% Y/Y) beats by $0.08M.As of December 31, 2021, the Company''s cash position…
   Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results  2022/03/29 11:30:00 PR Newswire
PRINCETON, N.J., March 29, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent…
   Soligenix GAAP EPS of -$0.31 misses by $0.01, revenue of $0.8M beats by $0.08M  2022/03/29 11:57:59 Seeking Alpha
Soligenix press release (SNGX): FY GAAP EPS of -$0.31 misses by $0.01.Revenue of $0.8M (-66.7% Y/Y) beats by $0.08M.As of December 31, 2021, the Company''s cash position…
   Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results  2022/03/29 11:30:00 PR Newswire
PRINCETON, N.J., March 29, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent…
   Soligenix''s COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants  2022/03/17 13:35:27 Benzinga
Soligenix Inc (NASDAQ: SNGX ) announced the results of a booster vaccination study using CiVax (heat-stable COVID-19 subunit vaccine program) in non-human primates (NHPs). The data demonstrated rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron … Full story available on Benzinga.com
   Soligenix rises on data from animal study for booster COVID-19 shot  2022/03/17 12:18:23 Seeking Alpha
Soligenix (SNGX), a late-stage biopharmaceutical company, is trading ~9% higher in the pre-market Thursday after announcing data from a booster vaccination study based on its…
   Soligenix to Present at Upcoming Investor Conferences  2022/01/06 12:30:00 Business Insider Markets
PRINCETON, N.J., Jan. 6, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need,

calendar